The study, recently published in The Journal of the American Medical Association, deduced that previous SARS-CoV-2 infection is associated with a statistically significant reduced hazard of breakthrough infection among recipients of both the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna) vaccines.